Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Zevra Therapeutics Inc.
Headquarters: Celebration , Fl , United States of America
Website: https://zevra.com/
Year Founded: 2006
Status: Public
Industry Sector: HealthTechnology
CEO: Neil F. McFarlane
Number Of Employees: 59
Enterprise Value: $376,535,333
PE Ratio: -3.15
Exchange/Ticker 1: NASDAQ:ZVRA
Exchange/Ticker 2: N/A
Latest Market Cap: $402,081,088
BioCentury | Mar 4, 2025
Deals
Kyorin picks Novartis amid innovative push; Abbvie taps Gubra for obesity: Deals Report
Plus: Hummingbird/Callio, Bridgene/Takeda, Magnet/Lilly, Gensaic/Novo, and more
BioCentury | Dec 10, 2024
Management Tracks
Toshinori Agatsuma, Daiichi’s head of research, passes away
Plus: Lange becomes CBO of Avidity and updates from CABS, BIO, Zevra and Achieve
BioCentury | Oct 24, 2024
Product Development
Rare Disease Spotlight: Niemann-Pick pipeline behind two approvals
Therapies aim to enhance lysosomal function to clear cholesterol and glycosphingolipids, mostly via small molecules
BioCentury | Oct 4, 2024
Data Byte
FDA’s September approvals include firsts for schizophrenia, Niemann-Pick
Subcutaneous formulations of Tecentriq and Ocrevus also among month’s seven new product approvals
BioCentury | Sep 23, 2024
Editor's Commentary
Rep. Pallone is wrong about priority review vouchers
Muddled thinking undermines support for an incentive that brings new drugs to kids
BioCentury | Aug 30, 2024
Data Byte
Nine PDUFA dates on FDA’s agenda in September
Decision on Zevra’s arimoclomol follows positive AdCom vote
BioCentury | Aug 9, 2024
Finance
Public equity report: Symbiotic Capital launches with $600M credit fund
Plus: TG Therapeutics’ $250M term loan, and public raises by Tenax, MindMed
BioCentury | Jun 27, 2024
Management Tracks
Foresite promotes Hyung Chun, Cindy Xiong to partner
Plus: Peter Flynn at the helm at Arialys, and updates from Augustine, CND, Parallel Bio and Zevra
BioCentury | Jan 5, 2024
Management Tracks
Friedman succeeding Hoos at Scorpion
Plus: 4DMT hires Noriyuki Kasahara as CSO, and updates from SV, Omega, AbbVie Ventures, Nikang, Immunome, Wugen, Zevra and Quris
BioCentury | Oct 10, 2023
Management Tracks
Amgen veteran Lenz named head of R&D at Neumora
Plus: Eaton leaving Editas as CTO, CBO and updates from Poseida, Zevra, Pheon, Lexicon and more
Items per page:
1 - 10 of 13